Olfactory neuroblastoma and neuroendocrine carcinoma of the anterior skull base: Treatment results at the M.D. Anderson Cancer Center

John R. Austin, Hazel Cebrun, Mathew M. Kershisnik, Adel K. El-Naggar, Adam S. Garden, Franco Demonte, Lawrence E. Ginsberg, Scott M. Lippman, Helmuth Goepfert

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Abstract

Updated information on the pathologic characterization and treatment of olfactory neuroblastoma (ON) and neuroendocrine carcinoma (NEC) diseases is presented. A series of patients with ON or NEC was evaluated and retrospectively staged using the UCLA system. The parameters evaluated were symptoms, age, sex, risk factor assessment, stage of disease, treatment, and clinical outcome. The median follow-up was 3 years (range, 18 months to 23 years). The predominant therapy (63%) for ON was combined surgery and radiotherapy. Surgery alone or in combination with ancillary treatment was used in 58% of patients with NEC. For the most recent years of the study, patients with NEC have been treated successfully with combined chemotherapy and radiotherapy. Seventy percent of the patients with ON and 75% of the patients with NEC were clinically free of disease during the defined follow-up period. Surgical therapy consisting of a craniofacial resection combined with postoperative radiotherapy has resulted in good local and long-term control of ON. Our experience indicates that combined chemoradiation is an appropriate therapeutic approach for NEC.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalSkull Base Surgery
Volume6
Issue number1
DOIs
StatePublished - 1996
Externally publishedYes

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Olfactory neuroblastoma and neuroendocrine carcinoma of the anterior skull base: Treatment results at the M.D. Anderson Cancer Center'. Together they form a unique fingerprint.

Cite this